NB-UVB 311 nm in Vitiligo: Dosing Protocols, Cohort Outcomes, and Practical Tips
Key Takeaways Backbone therapy for generalized/nonsegmental vitiligo; best responses on face/neck, slower on acral sites. Start low, escalate by 10–20% […]
F-VASI
Patient-Reported Outcomes in Vitiligo: DLQI, Vitiligo-Specific Scales, and What Counts as Clinically Meaningful
Key Takeaways Why PROMs? Pigment changes affect visibility, stigma, and function. PROMs help prioritize sites (e.g., face/hands) and set goals
Pediatric Vitiligo: Therapy, Safety, and Phototherapy Protocols
Key Takeaways First-line on face/neck: calcineurin inhibitors (tacrolimus 0.1% or pimecrolimus 1%) as steroid-sparing agents. Backbone for generalized disease: NB-UVB
Vitiligo Diagnosis: Wood’s Lamp & Dermoscopy — Criteria and Photo Protocol
Key Takeaways Wood’s lamp (365 nm) accentuates depigmented macules as bright blue-white/chalk-white with sharp rims. Dermoscopy helps confirm perifollicular islands, border
Tacrolimus 0.1% in Vitiligo: Efficacy by Anatomic Zone (Face/Neck vs Trunk vs Acral)
Key Takeaways Highest efficacy on face/neck with early perifollicular islands; moderate on trunk/limbs; limited on acral sites without phototherapy add-ons.
Tofacitinib ± NB-UVB in Vitiligo: Case Series and Open-Label Evidence
Key Takeaways Topical and oral tofacitinib show signals of repigmentation in case series/open studies, with best facial responses. NB-UVB appears
Ruxolitinib 1.5% Cream in Nonsegmental Vitiligo: TRuE-V1 and TRuE-V2 Phase 3 Results
Key Takeaways Two parallel phase 3 RCTs (TRuE-V1/V2) showed superiority vs vehicle on F-VASI at week 24, with continued gains
Topical Corticosteroids in Vitiligo: Potency Selection, Intermittent Regimens, and Safety
Key Takeaways First-line option on trunk/limbs; avoid continuous high-potency use on face, folds, genital skin—prefer calcineurin inhibitors there. Intermittent schedules
Pimecrolimus 1% vs Placebo for Facial Vitiligo: Randomized Controlled Trial Overview
Key Takeaways Pimecrolimus 1% cream showed superiority to vehicle on facial endpoints (F-VASI) over ~12–24 weeks in split-face and parallel-arm